• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

TG Therapeutics (TGTX)

Common Shares
Sell: $29.15|Buy: $29.22|Change: 0.25 (-0.85%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T),and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Address

2 Gansevoort Street
9th Floor
New York
NY
USA
10014

Telephone

+1 212 554-4484

Website

https://www.tgtherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
TG Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-03T08:30:00
TG Therapeutics Inc Third Quarter Earnings Results for 20262026-11-03T00:00:00
TG Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-04T08:30:00
TG Therapeutics Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
TG Therapeutics Inc Annual General Meeting for 20262026-06-12T09:30:00
TG Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-05T08:30:00
TG Therapeutics Inc First Quarter Earnings Results for 20262026-05-05T00:00:00
TG Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-03T08:30:00
TG Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-03T00:00:00
TG Therapeutics Inc Annual Report for 20252026-03-03T00:00:00

Previous key dates

NameKey Date
44(th) Annual J.P. Morgan Healthcare Conference.2026-01-13T13:30:00
8th Annual Evercore Healthcare Conference2025-12-02T12:30:00
TD Cowen Immunology & Inammation Summit2025-11-12T10:00:00
TG Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-03T08:30:00
TG Therapeutics Inc Third Quarter Earnings Results for 20252025-11-03T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T10:30:00
Cantor Global Healthcare Conference2025-09-03T10:20:00
TG Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-04T08:30:00
TG Therapeutics Inc Second Quarter Earnings Result for 20252025-08-04T00:00:00
TG Therapeutics Inc Annual General Meeting for 20252025-06-12T09:30:00
Goldman Sachs 46(th) Annual Global Healthcare Conference2025-06-10T10:40:00
Jefferies Global Healthcare Conference2025-06-04T12:50:00
TG Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-05T08:30:00
TG Therapeutics Inc First Quarter Earnings Results for 20252025-05-05T00:00:00
TG Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-03-03T08:30:00
TG Therapeutics Inc Fourth Quarter Earnings Result for 20242025-03-03T00:00:00
TG Therapeutics Inc Annual Report for 20242025-03-03T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.